An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies
Clinical trial NCT00002118 · COMPLETED
Trial details
- NCT number
- NCT00002118
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.